~" The results of this study demonstrate the presence of suppressive factor(s) in the tissue culture supernatants of cloned and freshly explanted malignant glioma cells. Culture supernatants obtained from these glial cell lines were demonstrated to have potent suppressive activity as evidenced by their ability to inhibit the proliferative response of normal human peripheral blood lymphocytes induced by phytohemagglutinin and anti-OKT3 monoclonal antibodies. The results further demonstrate the existence of a dose-response relationship between these supernatants and inhibition of mitogen-induced lymphocyte activation. Maximum production of suppressive activity by glial tumor cells was dependent on: 1) the number of tumor cells seeded in culture, 2) whether fetal calf serum was present, and 3) the duration of culture. The production of the suppressive factor(s) was not inhibited by the addition of inhibitors of prostaglandin E synthesis. Experiments designed to determine at what time during lymphocyte activation the suppressive factor was most effective demonstrated that the culture supernatants must be added during the first 24 hours of culture to exhibit inhibitory properties. Finally, proliferation of both the T-helper and T-suppressor/cytotoxic subsets was equally well inhibited by the glial tumor cell culture supernatants.
N
'UMEROUS clinical and experimental investigations indicate that immunological responsiveness to neoplasia appears to be an important facet of the biological response to malignancy. Temporal interrelationships remain speculative, and, although evidence suggests that general host immunocompetence inversely parallels the extent of the disease, the actual importance of host immunity in determining whether the host or tumor prevails is unclear. Additional deterrents to a complete understanding of these interrelationships emanate from paraneoplastic factors, such as "cahexia" (malnutrition found in patients with extensively infiltrative cancers). 14,15 These influences of general immunocompetence may be circumvented by confining investigations attempting to define tumorhost immunological interactions to patients with welllocalized disease. Patients with primary central nervous system (CNS) tumors are among the best suited for such studies because they are not as debilitated as those with other cancers, and malignant gliomas rarely metastasize beyond the confines of the parenchyma. Accordingly, any alteration of responsiveness in these patients may be ascribed to interactions of host immunity and the isolated neoplasm.
Investigations of the immunocompetence of patients with malignant gliomas have demonstrated a variety of defects in cell-mediated and humoral responsiveness. 2'4-7'13'16'17'19'21'24 Complementary studies have shown that autologous and homologous lymphocyte activity is suppressible by sera obtained from these patients. 4'12'24 Sequential evaluation of these patients further indicates that this humoral suppression is lost postoperatively only to reappear prior to clinical evidence of recurrence. 3 These data therefore suggest that the impairment of immunological reactivity observed in patients with malignant gliomas may be correlated with the presence and size of intracranial tumor as reported in experimental animal models harboring histologically similar neoplasms. TM These observations coupled with the more recent reports that glial cells are capable of releasing immunoregulatory moieties, such as interleukin-1, s and other immune-modifying substances 9 suggest that nonspecific host immune incompetence as observed in these patients results from altered lymphocyte function induced by suppressive factor(s) released from malignant glial cells. The present study supports this hypothesis by demonstrating the presence of suppressive factor(s) in the tissue culture supernatants of cloned and freshly explanted malignant glioma cells. The induced impairment interferes with early phases of T-cell activation, thereby preventing the normal progression of events required from immune responsiveness. Moreover, inhibition of normal lymphocyte activation extends to T-helper cells as well as to T-suppressor cells, suggesting that these tumor-derived suppressive moieties are effective by rendering potentially responsive T cells incapable of activation.
Materials and Methods

Lymphocyte Preparation
Heparinized venous blood obtained from healthy volunteers was separated on a Ficoll-Hypaque gradient.' After centrifugation at 400 G for 35 minutes, the lymphocyte layer was collected, washed twice in Hanks' balanced salt solution, and adjusted to 1 x 10 7 cells/ml in RPMI-1640 medium* containing 1% glutamine, nonessential amino acids, vitamins, and antibiotics.
The method employed to isolate T cells has been as described previously. ~6 Briefly, equal volumes of lymphocytes (1 x 107/ml) and 2.5 % neuraminidase-treated sheep erythrocytes (SRBC) were mixed, and SRBCabsorbed fetal calf serum (FCS) was added to attain a final concentration of 10%. The mixture was incubated at 4~ for 1 hour, and separated on a Ficoll-Hypaque gradient. The pellet containing the rosettes was treated with 0.83% NH4CI to lyse the SRBC's, and the lymphocytes were washed and counted. Less than 3% of these lymphocytes were B cells and less than 1% were monocytes, as determined by nonspecific esterase staining. 23 The T-helper (CD4 +) cells and T-suppressor/cytotoxic (CD8 +) cells were obtained by a panning technique. 22 Briefly, plastic petri plates (100 • 15 mm) were coated with affinity-purified anti-mouse immunoglobulin Gt at a concentration of I0 ug/ml in 0.05 M Tris-HCI buffer, pH 9.2, by incubating them with the solution for 40 minutes at room temperature. Unbound antibody was removed by washing the plates four times with Dulbecco's phosphate-buffered saline (PBS), pH 5.2, then once with Dulbecco's PBS, pH 7.2, containing 1% FCS. Negative selection was used to obtain either CD4 + or CD8 + T-cell subsets. Purified T cells at a concentration of 3 • 107/mt were resuspended in 2 ml of culture supernatant derived from hybridomas producing either anti-OKT4 or OKT8 monoclonal antibody and incubated at room temperature for 20 minutes. The cells were washed twice in Dulbecco's PBS, pH 7.2, containing 5% FCS, resuspended in 3 ml of this solution, and poured onto antibody-coated plates. The plates were incubated for 2 hours at 4~ The nonadherent cells (either CD4 + or CD8 +) were collected, and the plates were gently washed four times with Dulbecco's PBS, pH 7.2, containing 5% FCS. The cells were washed three times, resuspended in RPMI-1640 medium supplemented with 5 % FCS, and counted. Cell viability was determined and the percentage of CD4 + and CD8 + cells was calculated by indirect immunofluorescence techniques using anti-OKT4 and OKT8 monoclonal antibodies with fluorescein-labeled F(ab')2 fragments of mouse immunoglobulin. The CD4 + and CD8 + cell fractions were assessed to be approximately 95% pure.
Cell Cultures
Lymphocytes were adjusted to 1 x l0 6 cells/ml in modified RPMI-1640 medium containing 10% FCS (complete RPMI-1640 medium). The cells were dispensed in 200-ul volumes into 96-well microtiter plates at a final concentration of 2 x 105 cells/well. The triplicate cell cultures were stimulated with various concentrations of phytohemagglutinin (PHA) or anti-OKT3 monoclonal antibodies in a volume of 10 ul.z~ The cultures were incubated at 370C in a moist atmosphere of 5% CO2/95% room air for 72 hours with 0.5 ~zCi of tritiated thymidine (specific activity 6.7 Ci/mM) added 18 hours before termination.w The cells were havested with a multiple-sample harvester, and the radioactivity was determined by scintillation counting.
Glial Tumor Cells
Tumor specimens were obtained from patients at the time of surgery and the tumor was confirmed by standard procedures to be glioblastoma multiforme. The specimens were finely minced and placed in a culture solution of RPMI-1640 medium containing 10% FCS. The cells were incubated at 37~ in an atmosphere of 5% CO#95% room air, and the medium was changed every 3 to 5 days. When the cultures became confluent they were subcultured by treating the cells with trypsin ethylenediaminetetra-acetic acid; the cells were then washed and resuspended in RPMI-1640 medium containing 10% FCS. After 1 to 2 months in culture, the cells were found to be variable for glial fibrillary acidic protein (GFAP), but all had intermediate filaments as evidenced by electron microscopy. In addition to these cell lines, we also cultured cloned glial cell lines SNB-19, SNB-56, and U251 as described above. II All of these cell lines were positive for S-100 protein and GFAP with the exception of SNB-56 which tested negative for GFAP.
In certain experiments the glial cells were grown in the presence of the prostaglandin E (PGE) inhibitors ibuprofen and naproxen.* In addition, the concentration of PGE2 in the culture supernatants was assayed for PGE2 by radioimmunoassay.
Results
Production of a Suppressive Factor by Human Glial Tumors
Culture supernatants obtained from cloned glial cell lines and freshly explanted surgical specimens from patients with malignant gliomas were tested for their ability to inhibit the proliferative response of peripheral blood lymphocytes obtained from normal subjects to PHA and anti-OKT3 monoclonal antibodies. The results presented in Table 1 demonstrate that all culture supernatants have potent suppressive activity as evidenced by decreases in the lymphocyte proliferative response. This suppression is not the result of nonspecific cytotoxicity induced by the addition of glial tumorderived culture supernatants because the viabilities of lymphocytes cultured in the presence or absence of culture supernatants were similar.
The dose-response characteristics of two of these culture supernatants were determined to further define the effects on lymphocyte reactivity Accordingly, various concentrations of culture supernatants from the SNB-19 or SNB-56 cell lines were added at the initiation of lymphocyte cultures which were stimulated with either PHA or anti-OKT3 monoclonal antibodies (Fig. 1) . The results demonstrate the existence of a dose-response relationship between these culture supernatants and inhibition of the mitogen-induced lymphocyte activation. Thus, the addition of increasing amounts of the glioma-derived supernatants resulted in * Prostaglandin E inhibitors ibuprofen and naproxen manufactured by Sigma Chemical Co., St. Louis, Missouri. 
Production Kinetics of Glial Tumor-Derived Suppressive Factor
After demonstration of a suppressive factor in the glial tumor culture supernatants, experiments were then conducted to determine the kinetics of its production. The results in Fig. 2 show that production of the factor is dependent on the number of tumor ceils initially explanted and the duration of culture, and on the f Suppression = 100 -(cpm + culture supernatant)/(cpm + tissueculture medium) x 100. PHA --phytohemagglutinin. 
Effects of PGE Inhibitors on Release of Suppressive Factor
One possible explanation for the presence of suppressive factor(s) in the culture supernatants is the release of endogenous prostaglandins from explanted glial tumor cells. To test this hypothesis, 1 x 106 tumor cells/ml were cultured in the presence of various concentrations of the PGE inhibitors naproxen and ibuprofen. The supernatants from the cultures were collected after 48 hours of incubation and screened for inhibitory activity as previously outlined. The data presented in Table 2 indicate that inhibition of PGE synthesis and release does not affect the suppressive capabilities of the glioma-derived factor. In addition, the concentration of PGE2 in the culture supernatants was determined to be less than 0.5 pg/ml.
Effect of Time of Addition of Suppressive Factor and Lymphocyte Responsiveness
The previous experiments clearly show that glial tumor cells release immunosuppressive substances capable of impairing normal lymphocyte mitogenic responsiveness shortly after explantation in tissue culture. The following experiments were designed to determine at what time during lymphocyte activation the suppressive factor was most effective. Peripheral blood lymphocytes obtained from normal individuals were mitogenically stimulated, and culture supernatants from SNB-56 tumor cells were added at various times. The results in Fig. 3 show that this culture supernatant must be added during the first 24 hours of culture to exhibit inhibitory properties. Furthermore, addition of culture supernatants at the initiation of the mitogen-induced response produced the greatest degree of suppression. Addition at subsequent times resulted in little or no inhibition of lymphocyte reactivity. These data indicate that the glioma-derived suppressive factor interferes with an early mitogen signal for activation rather than with the later cellular proliferative events.
Effects of Suppressive Factor on Mitogen Responsiveness of CD4 § and CD8 § Cell Subsets
Having demonstrated that culture supernatants from gliomas induce significant suppression of the T-cell proliferative response, we next determined the effects of this factor on the mitogen-induced reactiveness of T-celt subsets. Purified Y cells obtained from normal individuals were fractionated into CD4 + and CD8 + subsets and subsequently stimulated with mitogen in the presence of varying concentrations of culture supernatants derived from the SNB-19 cloned glial tumor. Representative results of these experiments are presented in Fig. 4 , demonstrating that the responsiveness of CD4 + and CD8 + T cells is equally decreased by the glial-derived factor. These collective data indicate that * 1 x 106 tumor cells were incubated in the presence or absence of prostaglandin E (PGE) inhibitors. Culture supernatants were collected at 48 hours and screened for suppressor activity on the mitogen response of normal peripheral blood lymphocytes (PBL).
t Viability of tumor cells was calculated after 48 hours in culture with or without PGE inhibitors.
Percent suppression (see Table I for calculation) of the optimum mitogen response of normal PBL with or without PGE inhibitors added at the same concentration. The PGE inhibitors alone had no effect on the responses of the PBL to phytohemagglutinin (PHA) or anti-OKT3 monoclonal antibodies. Fig. 1 and percentage of suppression is calculated according to the formula used in Fig. 2. the effects of the glioma-derived suppressive factor are not confined to a specific T-cell subset, but instead broadly impair the responsiveness of all potentially reactive T cells.
Discussion
Initial and subsequent reports regarding the immunocompetence of patients with malignant gliomas have demonstrated an impairment of a cutaneous delayed type of hypersensitivity when compared to normal, healthy, or appropriate disease control groups. 4'3 Concurrent studies also revealed that the responsiveness of lymphocytes obtained from these patients to nonspecific mitogens and allogenic lymphocytes is significantly impaired. 2, 4, 7, 16, 17, 19, 21, 24 Furthermore, lymphocyte reactivity could be suppressed even more by sera obtained from those with malignant gliomas. 4'2' 24 More interesting, these sera suppressed not only the responsiveness of autologous lymphocytes obtained from patients but also impaired the responsiveness of normal homologous cells. Sequential evaluation of these patients further revealed that this humoral suppression was usually lost postoperatively only to reappear prior to clinical evidence of tumor recurrence. 3 These data, therefore, suggest that the impaired immunological reactivity observed in patients with malignant gliomas may be correlated with the presence and size of intracranial tumor, as reported in experimental animals harboring histologically similar neoplasms. 18 The results of the experiments presented in this report confirm and extend previous studies, indicating that malignant glial cells release suppressive factors that broadly impair normal T-cell responsiveness. 8 ' 9 The observation that this glial-derived suppressive factor is effective only during the initial events of lymphocyte activation emphasizes the significance of a previous report indicating that the T cells obtained from these patients are deficient in their cell-cycling capabilities following stimulation. 7 Thus, it may be hypothesized that the failure of appropriately stimulated T cells from glioma patients to expand into a pool of proliferating cells results from intrinsic cellular anomalies induced by glial-derived suppressive factors. The finding that glial tumors secrete immunomodulatory factors is not unexpected. Gately, et al.? ~ have demonstrated that malignant glial cells produce gtycosaminoglycan cell coats which protect the tumor cell from lymphocytemediated cytotoxicity. Cyst fluids obtained from some glioblastomas have been shown to be capable of suppressing lymphocyte function. ~ Additionally, cultured glioblastoma cells release a factor (MW 97,000) that inhibits interleukin-2-mediated effects on lymphocyte responsiveness. 8 The glioma-derived suppressor factor described in this paper (MW 25,000) differs from that described by Fontana, et al., 8 indicating that malignant glial cells possess the capability to produce a wide variety of immunomodulatory substances, both inhibitory and facilitatory.
How these alterations in T-lymphocyte function may occur is conjectural, yet there are unique shared features of the CNS and the immune system which warrant speculative comment. The finding that inhibition of prostaglandins did not abrogate the suppressive effects of the glioma cell factor suggests that the potential release of rich endogenous stores of prostaglandins within cerebral tissues does not play a role in modulating immune function in these patients. 2~ The observation that the mitogenic responsiveness of all T-cell subsets is equally impaired indicates that the effects of glial tumor-derived inhibitory factor are nonspecific in regard to lymphocyte susceptibility. However, the finding that that factor is only effective during the early stages of normal lymphocyte activation suggests that the effect is confined to specific phases of the cell cycle, such as transition from the resting state (Go) to G1. Correlating this observation with our previous findings, 7 it is interesting to hypothesize that impaired immune responsiveness in patients with malignant gliomas results from alterations in those molecular events that are required for the initiation of normal lymphocyte differentiation and growth.
In summary, the significant finding of this study is that glial tumor cells release inhibitory factors that modulate the initial events of normal lymphocyte blastogenic reactivity and, thus, are presumably important in effecting the cellular deficiencies observed in patients with malignant gliomas. Biochemical characterization of this factor(s) as well as elucidation of the cellular mechanism by which lymphocyte activation is modified is pivotal to understanding the immunobiological interactions of patients with malignant gliomas.
